Low Dose of Losartan Decreased Urinary Excretions of IgG, Transferrin, and Ceruloplasmin without Reducing Albuminuria in Normoalbuminuric Type 2 Diabetic Patients

Introduction

For the early detection of kidney damage in diabetic nephropathy, several studies including ours have reported that urinary excretions of various plasma proteins, such as IgG [1] [2], transferrin (Tf) [3] [4], and ceruloplasmin (CRL) [2] [5] are increased in diabetic patients with normoalbuminuria (NA) and that such increases in the urinary protein excretions at baseline predict future development of microalbuminuria (MA) [4] [5]. Thus, to prevent the progression of MA from NA, it seems important to search a therapy by which increased urinary excretions of plasma proteins mentioned above would be decreased. Previously, we have reported that glycemic control decreases these urinary proteins without change in urinary albumin excretion (UAE) in diabetic patients with NA [2]. However, few studies have examined the effect of therapy other than glycemic control on these urinary protein excretions in diabetic patients with NA. Therefore, the present study was designed to clarify the effect of angiotensin II receptor inhibitor (losrtan) on these urinary protein excretions in normoalbuminuric diabetic patients.

References

• 1 Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Kidney Int. 1988;  33 100-106
• 2 Narita T, Fujita H, Koshimura J, Meguro H, Kiatazto H, Shimotomai T, Kagaya E, Suzuki K, Murata M, Usami A, Ito S. Horm Metab Res. 2001;  33 370-378
• 3 Bernard AM, Ouled Amor AA, Goemaere-Vanneste J, Antonie JL, Lauwerys RR, Lambert A, Vandeleene B. Clin Chem. 1988;  34 1920-1921
• 4 Kazumi T, Hozumi T, Ishida Y, Ikeda Y, Kishi K, Hayakawa M, Yoshino G. Diabetes Care. 1999;  22 1176-1180
• 5 Narita T, Hosoba M, Kakei M, Ito S. Diabetes Care. 2006;  29 142-144
• 6 American Diabetes Association . Diabetes Care. 2006;  29 ((Suppl 1)) S4-S42
• 7 Narita T, Kitazato H, Koshimura J, Suzuki K, Murata M, Ito S. Nephron. 1999;  81 398-405
• 8 Koshimura J, Narita T, Sasaki H, Hosoba M, Yoshioka N, Shimotomai T, Fujita H, Kakei M, Ito S. Nephron Clin Pract. 2005;  100 c33-c37
• 9 Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Ann Intern Med. 1998;  128 982-988
• 10 Strippoli GFM, Craig M, Schena FP, Jonathan CC. J Am Soc Nephrol. 2005;  16 3081-3091
• 11 Brenner BM, Cooper ME, Zeeuw D de, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators . N Engl J Med. 2001;  345 861-869
• 12 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. for the Collaborative Study Group . N Engl J Med. 2001;  345 851-860
• 13 Viberti G, Wheeldon NM. for the MARVAL Study Investigators . Circulation. 2002;  106 672-678
• 14 Russo LM, Bakris GL, Comper WD. Am J Kidney Dis. 2002;  1 899-919
• 15 Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Kidney Int. 2000;  58 2129-2137
• 16 Hetzel GR, Plum J, Fusshöller A, Voiculescu A, Grünberg W, Grabensee B. Transplantation. 2005;  79 710-715
• 17 Narita T, Sasaki H, Hosoba M, Miura T, Yoshioka N, Morii T, Shimotomai T, Koshimura J, Fujita H, Kakei M, Ito S. Diabetes Care. 2004;  27 1176-1181
• 18 Deen WM, Bridges CR, Brenner BM, Myers BD. Am J Physiol. 1985;  249 ((Renal Fluid Electrolyte Physiol 18)) F374-F389
• 19 Myers BD. Am J Nephrol. 1990;  10 19-23
• 20 Tencer J, Frick IM, Öqvist B, Alm P, Rippe B. Kidney Int. 1998;  53 709-715
• 21 Osicka TM, Houlihan CA, Chan JG, Jerums G, Comper WD. Diabetes. 2000;  49 1579-1584
• 22 Tojo A, Onozato ML, Ha H, Kurihara H, Sakai T, Goto A, Fujita T, Endou H. Histochem Cell Biol. 2001;  116 269-276

Correspondence